TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02476851

Intervention type: DEVICE
Group type: OTHER
Intervention: POLFA (Needle Assembly)
Description: Each subject receives the same intervention and blood is drawn into both the INA and CNA. The difference is the order in which the CNA or INA is applied.

Intervention type: DEVICE
Group type: OTHER
Intervention: Kawasumi (Needle Assembly)
Description: Each subject receives the same intervention and blood is drawn into both the INA and CNA. The difference is the order in which the CNA or INA is applied.

Intervention type: DEVICE
Group type: OTHER
Intervention: Kawasumi (Needle Assembly)
Description: Each subject receives the same intervention and blood is drawn into both the INA and CNA. The difference is the order in which the CNA or INA is applied.
Study: NCT00921219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ivermectin
Description: Each subject will receive single doses of (i) 22.5 ml ivermectin oral solution (22.5 mg) and (ii) 10 x 3 mg tablets of ivermectin (30 mg) in 2 separate dosing periods. Doses will be administered 20 minutes after a standard breakfast.
Study: NCT03491319

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group X - head low tilt
Description: spinal anaesthesia was given with table in neutral positon. 10 degree head low position was maintained for 10 minutes following spinal anaesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group Y - head low tilt
Description: the table was put in 10 degree head low position before proceeding to give spinal anaesthesia. Head low position was maintained for 10 minutes following spinal

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Group C - neutral
Description: spinal anaesthesia was given with table in neutral positon. Patient was maintained in supine position for 10 minutes following spinal anaesthesia
Study: NCT01825915

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Hysterectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Supracervical Hysterectomy
Study: NCT03964220

Intervention type: DRUG
Intervention: Tiotropium Respimat®
Description: Tiotropium Respimat® 1.25 mcg (on top of baseline Inhaled Corticosteroid/Long-acting beta-agonist )

Intervention type: DRUG
Intervention: Inhaled Corticosteroid/Long-acting beta-agonist
Description: baseline low dose to medium/high dose, baseline medium dose ICS/LABA to high dose ICS/LABA, additional prescription/refill of high-dose-ICS/LABA following the first prescription of baseline high dose ICS/LABA
Study: NCT06520267

Intervention type: DRUG
Intervention: Antibiotic therapy
Description: Urine culture and antibiotic sensitivity tests were conducted to assess the bacteriological profile. The patients were then prescribed antibiotics based on susceptibility testing for a duration of 1 week.
Study: NCT01346657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifidipine & LipoCol
Description: The effect of LipoCol Forte® capsules on the pharmacokinetics of nifedipine after administering single-dose combination in healthy subjects.
Study: NCT04247854

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bacillus subtilis probiotic
Description: Bacillus probiotic which contains one confidential ingredient of Bacillus subtilis spores (2 x 1010 CFU/g). Over 5 days of interventional period, the patient receives one tablet (250 mg; 5 x 109 CFU) of probiotic per day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Over 5 days of interventional period, the patient receives 1 placebo tablet per day
Study: NCT03102398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-399 (5% Vardenafil HCl·3H2O, topical gel)
Description: 5% Vardenafil HCl·3H2O, topical gel, 2 drops (50ul, 2.5mg), q.d.
Study: NCT01914302

Intervention type: DEVICE
Intervention: Multiclix Lancing Device
Description: Characterize Blood Volume and Pain under normal use circumstances

Intervention type: DEVICE
Intervention: Fastclix Lancing Device
Description: Characterize Blood Volume and Pain under normal use circumstances

Intervention type: DEVICE
Intervention: Reli-On Lancing Device
Description: Characterize Blood Volume and Pain under normal use circumstances
Study: NCT01898117

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbo/cyclo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbo/cyclo + atezolizumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel + Atezolizumab
Study: NCT02816346

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shigella sonnei 53G
Description: Investigational Product: Shigella sonnei strain 53G (Lot 1794) Mode of Administration: Delivered with sodium bicarbonate orally after a 90 minute fast.~Dose: 500-1500 cfu (doses were to be increased or lowered based on results of preceding cohorts)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shigella sonnei 53G
Description: Investigational Product: Shigella sonnei strain 53G (Lot 1794) Mode of Administration: Delivered with sodium bicarbonate orally after a 90 minute fast.~Dose: 500-1500 cfu (doses were to be increased or lowered based on results of preceding cohorts)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shigella sonnei 53G
Description: Investigational Product: Shigella sonnei strain 53G (Lot 1794) Mode of Administration: Delivered with sodium bicarbonate orally after a 90 minute fast.~Dose: 500-1500 cfu (doses were to be increased or lowered based on results of preceding cohorts)
Study: NCT03723850

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: The brain is stimulated for 20 minutes with mild electrical current (maximum 2 mA) with two 7 cm x 5 cm electrodes placed on the scalp, using a standard 1x1 tDCS Clinical Trials device (Soterix Medica, NY), specialized for double-blinding.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: The brain is stimulated for 20 minutes with mild electrical current (maximum 2 mA) with two 7 cm x 5 cm electrodes placed on the scalp, using a standard 1x1 tDCS Clinical Trials device (Soterix Medica, NY), specialized for double-blinding.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active tDCS
Description: The brain is stimulated for 20 minutes with mild electrical current (maximum 2 mA) with two 7 cm x 5 cm electrodes placed on the scalp, using a standard 1x1 tDCS Clinical Trials device (Soterix Medica, NY), specialized for double-blinding.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: The brain is not stimulated for 20 minutes with mild electrical current, but instead a sham procedure is administered using a standard 1x1 tDCS Clinical Trials device (Soterix Medica, NY), specialized for double-blinding.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: The brain is not stimulated for 20 minutes with mild electrical current, but instead a sham procedure is administered using a standard 1x1 tDCS Clinical Trials device (Soterix Medica, NY), specialized for double-blinding.
Study: NCT01390012

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone tablet 6 mg
Description: Dexamethasone tablet 6 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone injection 4 mg
Description: Dexamethasone injection 4 mg
Study: NCT02367651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg
Description: Aqueous film-coated, oval-shaped, white tablets containing either 200 mg or 400 mg pazopanib

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets matching the 200 mg and 400 mg pazopanib tablets
Study: NCT04320225

Intervention type: DRUG
Intervention: Dexamethasone
Description: HD-DXM (orally at 40 mg daily for 4d )
Study: NCT04282863

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RM
Description: All patients were positioned in a lithotomy position. A uterine manipulator and a Foley catheter were inserted. Four trocars were used after pneumoperitoneum was obtained. Trocar sites varied according to different procedures. Generally, umbilical site for the scope and 8-10 cm lateral to the scope at 15 degrees for the arms are the most commonly adopted sites for robotic myomectomy.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: LM
Description: All patients were positioned in a lithotomy position. A uterine manipulator and a Foley catheter were inserted. Four trocars were used after pneumoperitoneum was obtained: a 10 mm port is inserted through the umbilicus to introduce the video-laparoscopic system. Other three accessory 5 mm trocar are inserted into the abdomen to the left lower quadrant, right lower quadrant, suprapubic area, for operative instruments and the suction irrigator cannula.
Study: NCT03313544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: NIVOLUMAB

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Cardiac MRI 6 MONTHS

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BLOOD SAMPLES
Description: biological (BNP and troponin)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: trans-thoracic echocardiography
Description: 1, 3 and 6 months
Study: NCT01524887

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immune Globulin Intravenous (Human), 10% Solution
Description: Intravenous infusion every 2 weeks over 18 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immune Globulin Intravenous (Human), 10% Solution
Description: Intravenous infusion every 2 weeks over 18 months

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Human albumin 0.25%
Description: Intravenous infusion every 2 weeks over 18 months
Study: NCT00378482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-675,206 (Tremelimumab)
Description: 15 mg/kg IV every 3 months as long as required
Study: NCT05682456

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-fat shake
Description: The high-fat shake consisted of 53% (w/v) fresh cream, 3% (w/v) sugar and 44% (w/v) water

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Reference shake
Description: The reference shake consisted of 43% (w/v) full cream milk, 48% (w/v) full cream yoghurt, 4% (w/v) lemonade, 4% (w/v) fantomalt (Nutricia B.V., the Netherlands) and 1% (w/v) wheat fiber
Study: NCT04752852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 8 mg/2 ml dexamethasone IV, 60 minutes before the induction of anaesthesia
Study: NCT03370393

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pathways for African-Americans' Success (PAAS)
Description: PAAS is a 6-week, technology-delivered, family-based youth risk intervention program. PAAS includes 6 sessions for parents and youth, and joint sessions in which they both engage on the same computer to integrate and practice the skills they have just learned in their separate sessions. Each session includes a review, a virtual discussion, and observing and interacting with four parent and four youth Avatars that reflect phenotypes of African Americans (AA), with voice-overs by AA parents and youth. Videos portraying family interactions and intrapersonal processes are integrated into each session to convey key points of the intervention along with interactive activities to promote skill-building and to reinforce learning. PAAS also includes a technology tutorial and an introductory session.
Study: NCT02199665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selinexor
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carfilzomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given PO or IV
Study: NCT03411122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: napabucasin
Description: Napabucasin will be administered at dose of 240 mg twice daily, every 12 hours (BID) on days 1-2 in period 1, and on days 1-11 in period 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytochrome P450 (CYP450) probe drugs or BCRP transporter substrate
Description: CYP450 probe drugs or BCRP transporter substrate will be administered once every period during days 1-4 in period 2, and days 6-9 in period 3.
Study: NCT02343822

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma Injection
Description: Plasma component of blood rich in growth factors~-during the injection, 5 needle fenestrations will be done to help stimulate blood flow to the area for healing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma Injection
Description: Plasma component of blood rich in growth factors~-during the injection, 5 needle fenestrations will be done to help stimulate blood flow to the area for healing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline Injection
Description: Saline~-during the injection, 5 needle fenestrations will be done to help stimulate blood flow to the area for healing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline Injection
Description: Saline~-during the injection, 5 needle fenestrations will be done to help stimulate blood flow to the area for healing
Study: NCT04212741

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: A+ HA(tm)
Description: oral solution of hyaluronic acid mixture

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral solution with no-active ingredients
Study: NCT03823339

Intervention type: DRUG
Intervention: Insulin degludec/liraglutide
Description: Patients will be treated with Insulin degludec/liraglutide (Xultophy®) at the treating physician's discretion and independent from the decision to include the patient in the study.
Study: NCT04283929

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Intervention 1 (Int1)
Description: This intervention will consist of the following additions to the EMR package. A link on the clinician's homepage to enrol a new HIV+ patient in the EMR which will open a form for (1) entering patient demographics (2) adding the contact home address or description of area, phone number (if available), (3) the peer educator contacts (4) recording the HIV+ result and date. A report will be added that is run every week to identify HIV+ patients not linked to care. The patients identified will be checked with paper records to ensure they have definitely not visited, then contacted after one, 2 weeks and 4 weeks if he/she did not show up. After two attempted contacts, if the patient is not yet linked to care he/she will be visited at home by the health facility social worker using routine home visits by health care providers.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Intervention 1 (Int1)
Description: This intervention will consist of the following additions to the EMR package. A link on the clinician's homepage to enrol a new HIV+ patient in the EMR which will open a form for (1) entering patient demographics (2) adding the contact home address or description of area, phone number (if available), (3) the peer educator contacts (4) recording the HIV+ result and date. A report will be added that is run every week to identify HIV+ patients not linked to care. The patients identified will be checked with paper records to ensure they have definitely not visited, then contacted after one, 2 weeks and 4 weeks if he/she did not show up. After two attempted contacts, if the patient is not yet linked to care he/she will be visited at home by the health facility social worker using routine home visits by health care providers.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Intervention 1 (Int1)
Description: This intervention will consist of the following additions to the EMR package. A link on the clinician's homepage to enrol a new HIV+ patient in the EMR which will open a form for (1) entering patient demographics (2) adding the contact home address or description of area, phone number (if available), (3) the peer educator contacts (4) recording the HIV+ result and date. A report will be added that is run every week to identify HIV+ patients not linked to care. The patients identified will be checked with paper records to ensure they have definitely not visited, then contacted after one, 2 weeks and 4 weeks if he/she did not show up. After two attempted contacts, if the patient is not yet linked to care he/she will be visited at home by the health facility social worker using routine home visits by health care providers.
Study: NCT00418756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Semi-synthetic antibiotic derivative of rifamycin B and is known to induce cytochrome P-450 (CYP) enzymes.
Study: NCT00362427

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hybrid 5 component DTaP, Vero IPV, Hep B and PRP-OMPC
Description: 0.5 mL, 4 doses, IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hybrid 5 component DTaP, Vero IPV, Hep B and PRP-OMPC
Description: 0.5 Ml, 4 doses, IM

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hybrid 5 component DTaP, Vero IPV, Hep B and PRP-OMPC
Description: 0.5 mL, 4 doses, IM with concommitant vaccines
Study: NCT04283929

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Intervention 2 (Int2)
Description: The data on availability of VL results in the EMR will come from a SQL statement to query the OpenMRS database. An alert will be fired if the patient has been enrolled for 8 months or more and does not have a viral load result in the EMR. The alert will be displayed on the patient summary and on the consult sheets, with text requesting the clinician orders a VL.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Intervention 2 (Int2)
Description: The data on availability of VL results in the EMR will come from a SQL statement to query the OpenMRS database. An alert will be fired if the patient has been enrolled for 8 months or more and does not have a viral load result in the EMR. The alert will be displayed on the patient summary and on the consult sheets, with text requesting the clinician orders a VL.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Intervention 3 (Int3)
Description: The data on VL results in the EMR showing detectable virus will come from a SQL statement to query the OpenMRS database. An alert will be fired if the patient has been enrolled for at least 12 months and the VL result in the EMR shows \> 1000 copies/mm3. The alert will be displayed on the patient summary and on the consult sheets requesting actions to address treatment failure (change first line medication, start second line medication, repeat VL, counselling on treatment adherence). A report will also be added to regularly check for patients with high viral load.
Study: NCT04532697

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Uncaria Rhynchophylla (Gou-Teng)
Description: Uncaria Rhynchophylla (Gou-Teng) is a kind of Chinese Medicine. All eligible subjects will be randomly assigned to receive a treatment of either Uncaria Rhynchophylla or placebo for 16 weeks followed by 8 weeks observation. The patient will be asked to take 1.2 g of the granule in the morning and another 1.2 g in the evening.
Study: NCT04752852

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 ml normal saline (0.9%) IV, 60 minutes before the induction of anaesthesia
Study: NCT01033903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: misoprostol
Description: 800 micrograms intravaginally ONCE
Study: NCT05888363

Intervention type: OTHER
Intervention: No Intervention
Description: Difference in outcomes in patients with rectal foreign bodies removed in the emergency department or in the operating room.
Study: NCT02446197

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Directed Exercise Group
Description: Combination of PT and OT activities that will be individually prescribed based on an evaluation by the therapy team completed pre-intervention. The activities will be added to the comprehensive inpatient rehabilitation program.
Study: NCT02689726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTL001+
Study: NCT02597439

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fatty acids

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02689726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldara
Description: 5% imiquimod cream
Study: NCT02476760

Intervention type: DRUG
Intervention: DPP-4 inhibitors
Description: Current exposure to DPP-4 inhibitors (ATC A10BH, A10BD07-A10BD13) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.

Intervention type: DRUG
Intervention: GLP-1 analogs
Description: Current exposure to GLP-1 analogs (ATC A10BX04, A10BX07) will be defined as a prescription duration plus a 30-day grace
Study: NCT00547300

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol ER
Description: Metoprolol ER once daily, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol
Description: Nebivolol once daily, oral administration
Study: NCT04532697

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All eligible subjects will be randomly assigned to receive a treatment of either Uncaria Rhynchophylla or placebo for 16 weeks followed by 8 weeks observation. The patient will be asked to take 1.2 g of the granule in the morning and another 1.2 g in the evening.
Study: NCT00010218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: karenitecin
Study: NCT02476760

Intervention type: DRUG
Intervention: Insulins
Description: Current exposure to insulin (ATC A10A) will be defined as any use of insulin between base cohort entry and the index day.

Intervention type: DRUG
Intervention: Biguanides
Description: Current exposure to biguanides (ATC A10BA) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
Study: NCT02840812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemonoxacin
Description: Nemonoxacin Malate Capsules 500mg single dose oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemonoxacin
Description: Nemonoxacin Malate Capsules 500mg single dose oral